Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Long-Term Clinical Benefit of PCSK9i in Addition to Statin Therapy in Patients With ST-Segment Elevation Myocardial Infarction. A Randomized, Open Label Study.

NCT05579418 is registered in ClinicalTrials.gov with Hamad Medical Corporation as lead sponsor.

NCT NCT05579418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05579418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Long-Term Clinical Benefit of PCSK9i in Addition to Statin Therapy in Patients With ST-Segment Elevation Myocardial Infarction. A Randomized, Open Label Study.
Lead sponsor
Hamad Medical Corporation
Phase
Phase 4
Overall status
Unknown status
Start date
November 1, 2022
Completion date
October 30, 2024
Enrollment
350 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias, stemi